Health Care

The earnings season has been disappointing and weighed on investor confidence through one of the worst starts to a new year. Nevertheless, there are some areas that may pull through the malaise, with decent growth propping up the sector-related exchange traded funds. Aggregate fourth quarter 2015 S&P 500 earnings-per-share are expected to fall 4.94% year-over-year, […]

U.S. regulators approved the sale of a lower-priced copy of an expensive blockbuster biologic drug, paving the way for further biosimilars to hit the market and supporting the outlook for the relatively new generic drugs exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global […]

The $3.5 billion First Trust Dorsey Wright Focus 5 ETF (NasdaqGM: FV) has helped exchange traded fund investors target some high-flying sectors, but the momentum strategy recently cut its biotech position for a defensive play. The First Trust Dorsey Wright Focus 5 ETF follows DWA’s relative strength ranking system where sector ETFs are compared to […]

Health care investors can now target a growing segment of the pharmaceutical industry through a relatively new generics drug exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global Generics & New Pharma Index, which tracks a number of global drug makers that generate significant […]

As volatility spikes and markets gyrate, some investors have turned to more conservative stocks and defensive sector exchange traded funds to ride out the storm. For instance, many have traditionally turned to defensive sectors like utilities, consumer staples and health care – sectors that would hold up in any economic cycle as U.S. consumers will […]

While the broad U.S. equities market strengthened Thursday, the biotechnology sector looked under the weather, with sector-related exchange traded funds slipping to 52-week lows. On Thursday, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB) fell 3.6% and SPDR S&P Biotech ETF (NYSEArca: XBI) dropped 3.5%. Year-to-date, IBB declined 19.2% and XBI decreased 26.4%. Both biotech ETFs […]

As the equities market experienced its worst start to a new year, exchange traded fund investors fled growth sectors and jumped into defensive stocks, along with betting on a valuation play. Investors’ eyes are on the tech space this week amid a spate of fourth quarter earnings results, but the technology sector was among the […]

Biotechnology stocks and sector-related exchange traded funds rallied late Wednesday but could not maintain their momentum after a high profile drug trial failure. Alkermes (NasdaqGS: ALKS), a central nervous-system drug developer, revealed two late-stage Phase 3 studies of its treatment for depressive disorder did not meet primary endpoints, Reuters reports. KMI shares plunged 42.3% Thursday, […]

As the markets digest fourth quarter earnings results, U.S. markets are expected to fall further into an earnings recession, with S&P 500 companies likely to show decline in profits for the third consecutive quarter. Nevertheless, there some sectors and related exchange traded funds that may pull through. Profits are expected to decline by 7.2% in […]

Breakout new drugs usually receive all the attention in the pharmaceuticals space, but generic drugs make up the bulk of the industry. Now, investors can target the rising growth in the generics space with a new sector-specific exchange traded fund. Van Eck Global’s Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) began trading Wednesday, according to […]

As investors try to shift around positions capitalize on short-term earnings moves, exchange traded funds that track the healthcare, telecom and tech sectors may outperform while the energy sector is largely expected to bring up the rear. Goldman Sachs analysts argue that the energy sector will depress U.S. fourth-quarter earnings and pressure growth for the […]

We are heading into the earnings season, and investors are growing concerned over the outlook for biotechnology stocks and sector-related exchange traded funds as bellwether Celgene Corp. (NasdaqGS: CELG) expects weaker-than-expected growth last year. Biotech stocks were among the worst performers Monday, with the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO), which focuses on small- and […]

Health care sector exchange traded funds are among the healthier segments of the U.S. equities market and could continue to grow stronger ahead. UBS equity strategists argue that investors should overweight the health care stocks due to the sector’s “earnings momentum, strong top-line growth, attractive dividend yield and potential for further share buybacks,” reports Luke […]

After a stellar October, the equities market and stock exchange traded funds had a more tepid November, with traders waiting for a potential rate hike in December. Over November, the Dow Jones Industrial Average was down 0.6%, the Nasdaq Composite was 0.4% lower and the S&P 500 dipped 1.1%. The best performing non-leveraged ETFs over […]

U.S. companies recently revealed their largest annual profit decline since the recession, suggesting that the economy and stock exchange traded funds are moving toward the late-cycle phase. Corporate America’s profits dropped to $2.1 trillion in the third quarter, or down 1.1% from the second quarter, and fell 4.7% year-over-year, the largest annual decline since the […]

Managed health care and service providers, along with sector-related exchange traded funds, look ill as health insurance giant UnitedHealth Group (NYSE: UNH) cuts its losses and plans to withdraw from the Affordable Care Act, or Obamacare. Among the worst performing ETFs on Thursday, the iShares U.S. Healthcare Providers ETF (NYSEArca: IHF) declined 4.3% and the […]

Actively managed mutual funds have been getting pummeled over the past few months, adding to the investment case for passively managed index-based investments and exchange traded funds as a better way to track the markets. According to a J.P. Morgan U.S. equity strategy note, 67% of mutual funds underperformed their benchmarks in the third quarter, […]

The recent plunge in oil prices and subsequent underperformance of the energy sector has been dragging on the S&P 500 Index. This last quarter’s revenue growth was -3.4%. If you excluded the energy sector, the revenue growth increased to 1.5%. What If You Could Buy The S&P 500 Without Energy Stocks? Enter the new ProShares […]

If you’re on team Hillary Clinton in the upcoming presidential election, you might want to trim down exposure to biotechnology stocks and sector-related exchange traded funds. “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on,” Democratic presidential candidate Hillary Clinton tweeted Monday, referring […]

While still highly unlikely, the Affordable Care Act, or so-called Obamacare, may be put through the wringer as it heads off to the Supreme Court, potentially posing a significant risk to the outperforming health care services and related exchange traded funds. Over the past year, the iShares U.S. Healthcare Providers ETF (NYSEArca: IHF) rose 24.8% […]

Health care service and provider stocks, along with related exchange traded funds, may fall under the weather as analysts point to sharp contraction in the sub-sector over the first quarter. According to analysts at JPMorgan Chase & Co. and Pierpont Securities LLC, the updated quarterly data on services showed that health care outlays declined at […]

After biotech stocks tumbled in the wake of drug pricing concerns and a disdain for growth stocks, biotechnology exchange traded funds show cheaper valuations and possibly present a buying opportunity for investors. “The recent price pressure may present a buying opportunity for investors interested in biotech firms,” according to Robert Goldsborough, fund analyst for Morningstar. […]

The economy is giving mixed signals and we are heading into a seasonally weak market condition. Nevertheless, exchange traded fund investors can still find opportunities in health care and consumer staples sectors. ETF Trends’ Tom Lydon recently sat down with Todd Rosenbluth, Director of ETF Research at S&P Capital IQ, to look at potential equity […]

Investors can take cues from American millionaires, as many wealthy participants expect to put more money into the stock market. In a recent CNBC Millionaire’s survey of 514 individuals with over $1 million in assets, millionaires plan to put 46% of their investment wealth into equities, followed by 21% into fixed-income and 14% into short-term […]

There is no doubt about it. Investors love sector exchange traded funds. As of mid-March, health care ETFs had raked in $1.8 billion since the start of the year and that is just one example. In March alone, investors poured $1.5 billion into financial services ETFs, nearly $940 million into technology funds and nearly $900 […]

Biotechnology exchange traded funds are looking under the weather, with investors taking profits after an impressive bull run. Meanwhile, some aggressive traders are capitalizing on Biotech’s misery with the leveraged exchange traded fund. The iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) saw $70 million in outflows over the past month, according to ETF.com data. The ETF […]

When the topic of health care sector mergers and acquisitions is raised, close attention is often paid to the biotechnology sub-sector. Conventional wisdom dictates that cash-rich blue chip pharmaceuticals firms facing patent cliffs will use some of that cash to acquire biotech firms and the blockbuster treatments produce by the those companies. If the recent […]

Investors may want to reduce exposure to high-yield dividend exchange traded funds in a rising interest rate environment. The Dow Jones U.S. Select Dividend Index, which includes 100 stocks screened for dividend growth and weighted by annual yield, has underperformed the S&P 500 Index by 4.5% since April 30, 2013, as yields on the benchmark […]

Forty-seven exchange traded funds hit all-time highs on Thursday. In a testament to the ongoing strength of the health care sector, now the third-largest in the S&P 500, 16 of the ETF’s touching all-time highs yesterday were health care funds. This is not a new phenomenon. In three-year period ending Feb. 12, the Health Care […]

The best performing exchange traded funds this year include some surprise moves and others adding on another stellar year. ETFs that track the solar, alternative energy, broker dealer and biotechnology sectors have outperformed this year, writes Trang Ho for Investor’s Business Daily. [Some of 2012’s Best Sector ETFs Kept Soaring in 2013] The Guggenheim Solar […]